Avanos Medical (AVNS) Cash from Financing Activities (2013 - 2026)

Avanos Medical has disclosed Cash from Financing Activities across 14 years of filings, most recently posting -$3.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 89.0% year-over-year to -$3.2 million; the TTM figure through Mar 2026 stood at -$11.1 million (up 85.68% YoY), while the FY2025 annual figure was -$37.0 million, up 24.64% from the prior year.
• Cash from Financing Activities came in at -$3.2 million for Q1 2026 at Avanos Medical, down from -$2.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $105.7 million in Q1 2022 to a low of -$114.7 million in Q4 2023.
• Average Cash from Financing Activities over 5 years is -$7.5 million, with a median of -$5.0 million recorded in 2024.
• Year-over-year, Cash from Financing Activities soared 52950.0% in 2022 and plunged 4057.14% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$21.9 million in 2022, then plunged by 423.74% to -$114.7 million in 2023, then jumped by 76.11% to -$27.4 million in 2024, then surged by 90.15% to -$2.7 million in 2025, then retreated by 18.52% to -$3.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$3.2 million in Q1 2026, -$2.7 million in Q4 2025, and -$2.0 million in Q3 2025.